An explanation for this phenotype was supplied by the discovery of an activating mutation in Janus kinase 2 .1 However, the same mutation occurs in essential thrombocytosis and major myelofibrosis, which are diseases with overlapping phenotypes but distinctly different organic histories. Although it is certainly undisputed that JAK2 V617F can create a myeloproliferative phenotype, the JAK2 V617F allele burden cannot be the sole explanation for the pathogenesis of these three different diseases, because it overlaps among them substantially.Interestingly, the medication has demonstrated synergic results in combination with bortezomib in a Multiple Myeloma pet model and in combination with rituximab in a p53-mutated Mantle Cell Lymphoma animal model. These total results suggest the potential usage of Acadra within combination therapy in such indications. Dr. Kenneth Weissmahr comments,’The very encouraging nonclinical data is showing the potential of Acadra in Multiple Myeloma and Mantle Cell Lymphoma which raises substantially the market potential of this drug. These results validate our business design and now we anticipate partner this program with a business that guarantees its development to market.’ Acadra was in-certified by Advancell from the University of Barcelona until November 2009, when the Spanish biotech licensed-back its privileges from BTG.
PRESS RELEASE CHICAGO – To provide guidance on best practices for reimagining traditional associations between physicians and hospital executives, the American Medical Association and American Medical center Association today released a new set ofguiding principlesfor getting clinical skills and business insights collectively at the leadership level to foster even more collaborative and cohesive decision-making at hospitals and health systems.